← Leaderboards
Stephen Gottschalk
Baylor College Of Medicine
$13,145,706
Attributed
$19,758,415
Total exposure
19
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2007–25$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,758,415 · 19
By mechanism
R01$12,157,844 · 4
P01$4,476,877 · 3
P50$1,344,585 · 1
T32$830,706 · 1
R21$802,750 · 1
M01$145,653 · 9
Top collaborators
- Irina V Balyasnikova7 shared
- Xiaotong Song5 shared
- Kai W Wucherpfennig5 shared
- Christopher C. Derenzo4 shared
- Cliona M Rooney1 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Helen E Heslop$25,308,937
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteCellsImmunotherapyTumorSafetyImmuneMalignant NeoplasmsCytokineAntigensIn VivoClinical TrialsNeoplastic CellProductionPeripheral BloodSiteClinical ResearchAdoptive TransferBaseImmunityCell PhysiologyInfusion ProceduresEnvironmentTumor AntigensIn Complete Remission
Grant awards (50)
Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors$754,519
R01 · FY2025 · CA
T32 Training Program in Pediatric Immuno-Oncology and Immunotherapy$140,944
T32 · FY2025 · CA · contact PI
Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors$716,793
R01 · FY2024 · CA
T32 Training Program in Pediatric Immuno-Oncology and Immunotherapy$227,609
T32 · FY2024 · CA · contact PI
Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors$719,445
R01 · FY2023 · CA
T32 Training Program in Pediatric Immuno-Oncology and Immunotherapy$235,013
T32 · FY2023 · CA · contact PI
Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors$734,126
R01 · FY2022 · CA
Lentiviral Gene Therapy and Genome Editing for X-linked Severe Combined Immunodeficiency$576,217
P01 · FY2022 · HL · contact PI
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy$520,925
R01 · FY2022 · NS
T32 Training Program in Pediatric Immuno-Oncology and Immunotherapy$227,140
T32 · FY2022 · CA · contact PI
Lentiviral Gene Therapy and Genome Editing for X-linked Severe Combined Immunodeficiency$576,217
P01 · FY2021 · HL · contact PI
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy$524,691
R01 · FY2021 · NS
Lentiviral Gene Therapy and Genome Editing for X-linked Severe Combined Immunodeficiency$576,217
P01 · FY2020 · HL · contact PI
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy$527,915
R01 · FY2020 · NS
Lentiviral Gene Therapy and Genome Editing for X-linked Severe Combined Immunodeficiency$582,121
P01 · FY2019 · HL · contact PI
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy$531,045
R01 · FY2019 · NS
Lentiviral Gene Therapy and Genome Editing for X-linked Severe Combined Immunodeficiency$590,189
P01 · FY2018 · HL · contact PI
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy$548,582
R01 · FY2018 · NS
Reprogramming of T cells for the Treatment of Melanoma$995,664
R01 · FY2016 · CA
Reprogramming of T cells for the Treatment of Melanoma$995,664
R01 · FY2015 · CA
IL13Ra2 targeted T-cell therapy for glioma$394,125
R21 · FY2015 · NS
Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine$325,652
R01 · FY2015 · CA
Reprogramming of T cells for the Treatment of Melanoma$995,664
R01 · FY2014 · CA
IL13Ra2 targeted T-cell therapy for glioma$408,625
R21 · FY2014 · NS
Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine$315,831
R01 · FY2014 · CA
Reprogramming of T cells for the Treatment of Melanoma$965,794
R01 · FY2013 · CA
Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine$306,012
R01 · FY2013 · CA
Improving T Cell Therapies for Nasopharyngeal Cancer$264,825
P01 · FY2013 · CA · contact PI
Reprogramming of T cells for the Treatment of Melanoma$1,014,415
R01 · FY2012 · CA
Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine$329,757
R01 · FY2012 · CA
IMPROVING T CELL THERAPY OF NASOPHARYNGEAL CANCER$259,217
P01 · FY2012 · CA · contact PI
Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine$335,350
R01 · FY2011 · CA
IMPROVING T CELL THERAPY OF NASOPHARYNGEAL CANCER$260,344
P01 · FY2011 · CA · contact PI
T Cell Therapy Targeting LMP1 and 2 in EBV+VE Lymphomas$245,499
P50 · FY2011 · CA · contact PI
ADMINISTRATION OF HER2 CHIMERIC RECEPTOR AND TGFBETA DOMINANT NEGATIVE RECEPTOR$10,686
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: ADMINISTRATION OF LMP1- AND LMP2-SPECIFIC CYTATOXIC T-LYMPHOCYTE$5,541
M01 · FY2011 · RR · contact PI
HUMORAL AND CELLULAR IMMUNE RESPONSES TO TUMOR ASSOCIATED ANTIGENS (TAA) PATIENT$792
M01 · FY2011 · RR · contact PI
T Cell Therapy Targeting LMP1 and 2 in EBV+VE Lymphomas$296,903
P50 · FY2010 · CA · contact PI
IMPROVING T CELL THERAPY OF NASOPHARYNGEAL CANCER$269,289
P01 · FY2010 · CA · contact PI
CLINICAL TRIAL: ADMINISTRATION OF LMP1- AND LMP2-SPECIFIC CYTATOXIC T-LYMPHOCYTE$54,353
M01 · FY2010 · RR · contact PI
ADMINISTRATION OF HER2 CHIMERIC RECEPTOR AND TGFBETA DOMINANT NEGATIVE RECEPTOR$2,289
M01 · FY2010 · RR · contact PI
T Cell Therapy Targeting LMP1 and 2 in EBV+VE Lymphomas$300,261
P50 · FY2009 · CA · contact PI
IMPROVING T CELL THERAPY OF NASOPHARYNGEAL CANCER$264,909
P01 · FY2009 · CA · contact PI
CLINICAL TRIAL: ADMINISTRATION OF LMP1- AND LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTE$51,554
M01 · FY2009 · RR · contact PI
T Cell Therapy Targeting LMP1 and 2 in EBV+VE Lymphomas$257,740
P50 · FY2008 · CA · contact PI
IMPROVING T CELL THERAPY OF NASOPHARYNGEAL CANCER$257,332
P01 · FY2008 · CA · contact PI
CLINICAL TRIAL: ADMINISTRATION OF LMP1- AND LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTE$17,538
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ADMINISTRATION OF EBV-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOLLOWING$2,677
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ADMINISTRATION OF LMP1 AND LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES$223
M01 · FY2008 · RR · contact PI
T Cell Therapy Targeting LMP1 and 2 in EBV+VE Lymphomas$244,182
P50 · FY2007 · CA · contact PI